PharmaMar has Requested the Process of Re-Examination for Aplidin® from the EMA

- PharmaMar (MCE: PHM) has announced the initiation of the re-examination process by the European Medicines Agency (EMA) for Aplidin® (plitidepsin) for the indication of relapsed and refractory multiple myeloma.      (Logo: http://photos.prnewswire.com/prnh/20150203/727958-b ) PharmaMar believes that this novel molecule could become part of the therapeutic arsenal available for the treatment of multiple myeloma in Europe. It is worth noting that the re-examination procedure is handled by the EMA's CHMP and usually lasts around 4 months. It concludes with either the confirmation of the negative opinion or with the issuing of a new positive opinion by the CHMP. After finalizing this process of re-examination, the European Commission will be in charge of emitting the final verdict on the Marketing Authorization Application (MAA) for Aplidin® (plitidepsin), which could arrive around June or July, 2018.   Media Relations (+34-6387-96215) and Investor Relations (+34-9144-44500)